How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →
API Evangelist API Evangelist
Discovery
Learnings
Guidance
Toolbox
Alignment
API Evangelist LLC

Nimbus Therapeutics to Present New Preclinical Data on Selective SIK2 Inhibition in Rheumatoid Arthritis at ACR Convergence 2026

calendar_today November 5, 2026 person Cindy Fung domain nimbus-therapeutics

— Selective SIK2 inhibitors reduced disease activity in a mouse model of rheumatoid arthritis to levels comparable to approved therapies etanercept and upadacitinib — BOSTON, Mass. — November 5, 2026 — Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a computational drug discovery company developing breakthrough small molecule medicines through advanced structure-based design and AI-enabled chemistry, … Continue reading “Nimbus Therapeutics to Present New Preclinical Data on Selective SIK2 Inhibition in Rheumatoid Arthritis at ACR Convergence 2026” The post Nimbus Therapeutics to

open_in_new Read original post